Background: worldwide, breast cancer is the most common malignancy among women and there is a deep need for precise novel methodologies for breast cancer (BC) diagnosis. Major advances in cancer control will be successfully achieved with early cancer detection. So, recent trends are going toward using circulating non-coding RNA as diagnostic tool for their critical role in cancer detection.
Aim: retrieve non coding RNA that is mechanistically linked to breast cancer stem cell with validation of the results in a group of breast cancer patients versus control groups to evaluate their usefulness as a potential biomarker in breast cancer diagnosis.
Patients and Methods: we retrieved LncRNA that is linked to stem cell differentiation and specific to BC utilizing bioinformatics tools. Then we validated this biomarker in serum of 30 patients with BC, 12 patients with benign breast lesion and 12 healthy volunteers using RT-qPCR. We evaluate the power of diagnosis of the serum profiling system using ROC curve analysis.
Results: hoxd antisense growth-associated long non coding RNA (HAGLR) had great sensitivity and specificity for differentiating BC from patients with benign breast lesion and also from healthy controls.
Conclusion: the chosencirculatory RNA based biomarker can be used as a potential diagnostic biomarker for BC. In addition it could be therapeutic target.